MedCity News April 23, 2021
Frank Vinluan

Covid-19 showed how technology can upend the old ways of clinical trials. Panelists at MedCity’s INVEST conference said it’s highlighting the importance of improving clinical trial diversity so that tests of new therapies and vaccines reflect the population of patients that they will treat in the real world.

Before Covid-19, the classic clinical trial was very much an in-person process. Drug companies, or the contract research organizations (CRO) hired to run the studies, recruited investigators and patients. Those patients physically entered a clinical site to receive the experimental treatment, and they returned for follow-up visits to assess how they’re responding to the medicine. Covid-19 showed how technology can upend the old ways of clinical trials. It has also highlighted the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Healthcare System, Patient / Consumer, Pharma, Pharma / Biotech, Public Health / COVID, Technology
Related Articles:
11 drugs now in shortage
AbbVie tries to reassure investors on Humira biosimilar threat
FDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder
This Biotech Startup Aims To Speed Up Drug Testing On Animals
Scientists reveal new method that could reduce waste from drug manufacturing

Share This Article